Blenrep delays disease progression by nearly 3X versus Darzalex
GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreGlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by…
The European Medicines Agency has agreed to review Regeneron…
Bristol Myers Squibb has received a positive opinion…
A dysregulated immune response against viruses that cause hepatitis…
Obesity, a history of heavy smoking, and limited sleep…
STAR-LLD, a continuous infusion of low-dose lenalidomide into the…